Astellas v. Lupin: Consent Judgment in Mirabegron Extended-Release Tablet Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Astellas Pharma, Inc. c. Lupin Limited |
| Numéro de dossier | No. 1:24-cv-00939 (D. Del.) |
| Tribunal | Tribunal fédéral de première instance pour le district du Delaware |
| Durée | Aug 2024 – Feb 2026 555 days |
| Résultat | Plaintiff Win — Consent Judgment |
| Brevets en cause | |
| Produits incriminés | 25 mg Mirabegron Extended-Release Tablets (Lupin ANDA No. 209485) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Tokyo-headquartered global pharmaceutical company and holder of patents protecting Myrbetriq® (mirabegron) extended-release tablets.
🛡️ Défendeur
One of India’s largest generic pharmaceutical manufacturers, challenging branded drug exclusivities in the U.S. market.
Brevets en cause
This landmark case involved four utility patents protecting the extended-release formulation technology of Myrbetriq® (mirabegron). Utility patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect functional inventions rather than ornamental design.
- • US12059409B1 (application no. US18/613270) — Extended-release tablet formulation
- • US X,XXX,780 — Formulation technology
- • US X,XXX,451 — Composition and release mechanism
- • US X,XXX,189 — Related innovations
Developing a generic drug or new formulation?
Vérifiez avant le lancement si votre produit pharmaceutique est susceptible d'enfreindre ces brevets ou des brevets connexes.
Le verdict et l'analyse juridique
Résultat
The District Court entered a consent judgment in favor of Astellas on February 19, 2026. No damages were awarded, consistent with the injunctive and prospective nature of Hatch-Waxman litigation, where relief typically takes the form of market exclusion rather than retrospective monetary compensation.
Key Findings Under the Consent Judgment
The consent judgment contained several legally significant admissions by Lupin:
- Validity and Enforceability: Lupin expressly admitted that the ‘780, ‘451, ‘409, and ‘189 patents are valid and enforceable — a significant concession that forecloses future invalidity challenges by Lupin with respect to these ANDA products.
- Infringement: Lupin admitted that at least one claim of each of the four asserted patents is infringed by the Lupin ANDA Products. This claim-by-claim framing is notable — it confirms infringement without limiting the admission to specific claims, preserving Astellas’s enforcement posture.
- Market Exclusion: Lupin is enjoined from making, using, selling, offering for sale, importing, or distributing the ANDA products in the United States until expiration of all four patents, including any patent term extensions (PTEs), patent term adjustments (PTAs), pediatric exclusivity, or other regulatory exclusivities. This is the maximum available relief in Hatch-Waxman litigation.
- Dismissal of All Pending Claims: All complaints across the four consolidated civil actions were dismissed without prejudice and without costs or attorneys’ fees — preserving both parties’ rights to future enforcement or defense in different contexts.
- Retained Jurisdiction: The court explicitly retained jurisdiction to enforce the consent judgment, with both parties waiving venue and personal jurisdiction defenses for enforcement proceedings — a critical enforcement provision for Astellas.
The structure of this consent judgment reflects a sophisticated litigation strategy by Astellas. By obtaining explicit admissions of validity and infringement across four separate patents, Astellas significantly strengthens its IP enforcement position against Lupin specifically. The breadth of the injunction — extending through PTEs, PTAs, and pediatric exclusivity — ensures that regulatory extensions of patent life are fully captured.
The multi-patent assertion strategy is particularly significant. Layering formulation, compound, and method-of-use claims across multiple patent families creates redundant barriers that are difficult for generic challengers to overcome simultaneously. The ‘780, ‘451, ‘409, and ‘189 patents represent precisely this kind of coordinated portfolio architecture.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in generic pharmaceutical development and branded lifecycle management. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View all related patents in the mirabegron space
- See leading companies in OAB formulation patents
- Understand claim scope and design-around patterns
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Input your generic drug formulation or target API
- L'IA identifie les brevets de formulation susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Mirabegron extended-release formulations
4 brevets revendiqués
Protecting Myrbetriq® technology
Strong Portfolio
Multi-layered patent protection
✅ Points clés à retenir
Explicit validity and enforceability admissions in consent judgments create strong estoppel and bolster future litigation postures.
Rechercher la jurisprudence connexe →Multi-patent strategies asserting overlapping formulation, compound, and method claims remain the gold standard in Hatch-Waxman.
Explorer les précédents →Foire aux questions
The case involved four patents protecting Myrbetriq® (mirabegron) extended-release tablet formulations, identified in the consent judgment as the ‘780, ‘451, ‘409, and ‘189 patents, including U.S. Patent No. US12059409B1 (application no. US18/613270).
Lupin admitted validity, enforceability, and infringement of all four asserted patents in connection with its ANDA No. 209485, agreeing to a market exclusion injunction through patent expiration.
It reinforces Astellas’s exclusivity over Myrbetriq® formulation technology and signals the strength of multi-patent portfolio strategies against generic ANDA challengers in the OAB therapeutic space.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- United States District Court for the District of Delaware — Case 1:24-cv-00939
- Office américain des brevets et des marques — Base de données contenant le texte intégral et les images des brevets
- U.S. Food & Drug Administration — Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
- Cornell Legal Information Institute — Hatch-Waxman Act (21 U.S.C. § 355)
- PatSnap — IP Intelligence Solutions for Pharma & Biotech
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.